Verified public updates from Plutus Investment Group and our portfolio companies.
Navro announced a strategic partnership with Strada to embed global payment execution into payroll workflows, supporting salary, statutory and third-party disbursements across 95 countries.
Source: NavroMPC Therapeutics launched MitoStem™, an ex vivo metabolic enhancer designed to improve CAR-T and engineered cell therapy performance by increasing durable, stem-like T-cell populations.
Source: Plutus / MPC TherapeuticsOxford Cancer Biomarkers announced a Licence of Technology agreement with Oxford University Innovation to extend the clinical application of its ToxNav® test for chemotherapy toxicity risk.
Source: Plutus / Oxford Cancer BiomarkersMira Precision Health announced the U.S. launch of ToxNav® Advantage™, a clinically validated pharmacogenomic assay for fluoropyrimidine toxicity risk.
Source: Oxford Cancer Biomarkers / Mira Precision Health